
Qatar advances data-driven sustainability with circular economy indicators framework
Additionally, the expert stated that defining indicators is a foundational step for effective policymaking

Additionally, the expert stated that defining indicators is a foundational step for effective policymaking

Stock pickers have long sought to beat the market, and most continue to fail, with the rate of underperformance of U.S. large-cap mutual funds, after fees, against the S&P 500 between 80%-90% of all funds over a decade. But there are ways to think about generating what is known as alpha — outperformance of a ...

Sources of growth in the U.S. economy are “narrow,” while large parts of the country’s output are “weak or contracting,” according to analysts at UBS. In a note, the analysts including Jonathan Pingle and Alan Detmeister argued that the American economy’s outlook from this year to 2028 is heavily reliant on artificial intelligence investment, which ...
At a time when banks have tokenization, stablecoin and blockchain projects in the works, senior leaders will exchange ideas at a New York conference.

Bitcoin Treasury Goal Remains $100 Million LAS VEGAS, Jan. 27, 2026 /PRNewswire/ -- Hyperscale Data, Inc. (NYSE American: GPUS), an artificial intelligence ("AI") data center company anchored by Bitcoin ("Hyperscale Data" or the "Company"), today announced that its Bitcoin treasury,...
Hammond Power Solutions more than doubled its revenue in the last few years, CEO is bullish on the future

Managed futures ETF manager discusses his fund and outlook.
Net Income of $1.44 million in the December 2025 Quarter, Down 15% from the Sequential Quarter but Up 65% from the Comparable Quarter Last Year

Baron Opportunity Fund topped the list.

What if the AI bubble bursts in 2026? Here's how you can invest in a safer way in case AI stocks crash.

These undervalued stocks with wide economic moats and consistent cash flows look attractive.
STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its cash burn rate and financing strategy.